Sign inJoin waitlistJoin the waitlist

Randy Sweis

Associate Professor of Medicine · University of Chicago Medical Center

Credentials: · · · · ·

History

University of Chicago Medical Center
Present

University of Chicago Medical Center
2014–2016
University of Michigan Hospitals & Health Ctrs.
2011–2014
University of Chicago Division of the Biological Sciences, The Pritzker School of Medicine
2006–2010

Research

WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers
Clinical Cancer Research · 2019 · 609 citations
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Clinical Cancer Research · 2022 · 339 citations
T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection
Cancer Immunology Research · 2018 · 338 citations

JL
Jason Luke
8 papers
Walter Stadler
8 papers
Alexander Pearson
7 papers
Gary Steinberg
7 papers
Russell Szmulewitz
7 papers
Peter O'Donnell
6 papers
Sean Pitroda
6 papers · 1 as a resident
Thomas Gajewski
6 papers
Stanley Liauw
4 papers
Alec Kacew
3 papers
Emily Higgs
3 papers · 2 as a resident
Funda Meric-Bernstam
3 papers

Grants

Elucidating Immunotherapy Resistance Mechanisms in Non-T Cell-Inflamed Bladder Cancer
National Cancer Institute · K08
Contact PI · $850.7K · University of Chicago
2018–2022

Clinical trials

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2019–2027